Stem cell startup proclaims ‘inflection point’ for medicine as mass production nears
Thursday, 7 August 2025 () It’s harvest day at the Karolinska Institute in Stockholm. As sunshine bathes the leafy university campus, scientists inside the labs work under cool fluorescent light. Clad in green protective gear, they tend meticulously to test tubes within hermetically sealed cleanrooms. The containers hold the fruits of today’s labour: mesenchymal stem cells (MSCs). Each cell is barely a quarter the width of a human hair but wields remarkable power. MSCs reduce inflammation, repair damaged tissue, and modulate the immune system. They can treat chronic diseases and delay ageing. They may even prevent illness before it begins. But to become a mainstay…
Thursday, 7 August 2025 ()
It’s harvest day at the Karolinska Institute in Stockholm. As sunshine bathes the leafy university campus, scientists inside the labs work under cool fluorescent light. Clad in green protective gear, they tend meticulously to test tubes within hermetically sealed cleanrooms. The containers hold the fruits of today’s labour: mesenchymal stem cells (MSCs). Each cell is barely a quarter the width of a human hair but wields remarkable power. MSCs reduce inflammation, repair damaged tissue, and modulate the immune system. They can treat chronic diseases and delay ageing. They may even prevent illness before it begins. But to become a mainstay…